NEW
YORK, Feb. 13, 2024 /PRNewswire/ -- BrainStorm
Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of
adult stem cell therapeutics for neurodegenerative diseases, today
announced that it will provide a corporate update at the 17th
Annual European Life Sciences CEO Forum to take place 28 - 29
of February, 2024 in Zurich,
Switzerland.
Presentation Details
Presentation Date: Wednesday, 28th
February
Time: 13:40h CET
Location: Panorama Room (Track C), Hilton Zurich Airport
Hotel
Dr. Stacy Lindborg, Co-CEO of
BrainStorm, will also participate in a panel discussion Neuro
Advances Panel: Highlighting the Main Opportunities, at 17:20h
on February 28.
Dr. Lindborg and Mr. Chaim
Lebovits, President and CEO of Brainstorm, will be available
for in-person meetings with conference attendees, February 28 – 29, and virtual meetings
March 6 – 8.
About BrainStorm Cell Therapeutics
Inc.
BrainStorm Cell Therapeutics Inc. is a leading developer of
innovative autologous adult stem cell therapeutics for debilitating
neurodegenerative diseases. BrainStorm holds the rights to clinical
development and commercialization of the NurOwn® technology
platform used to produce autologous MSC-NTF cells through an
exclusive, worldwide licensing agreement. Autologous MSC-NTF cells
have received Orphan Drug designation status from the U.S. Food and
Drug Administration (FDA) and the European Medicines Agency (EMA)
for the treatment of amyotrophic lateral sclerosis (ALS).
BrainStorm has completed a Phase 3 trial in ALS (NCT03280056); this
trial investigated the safety and efficacy of repeat-administration
of autologous MSC-NTF cells and was supported by a grant from the
California Institute for Regenerative Medicine (CIRM CLIN2-0989),
and another grant from the ALS Association and I AM ALS. BrainStorm
completed under an investigational new drug application a Phase 2
open-label multicenter trial (NCT03799718) of autologous MSC-NTF
cells in progressive MS and was supported by a grant from the
National MS Society (NMSS).
Notice Regarding Forward-Looking
Statements
This press release contains "forward-looking statements" that are
subject to substantial risks and uncertainties, including
statements regarding meetings with the U.S. Food and Drug
Administration (FDA), Special Protocol Assessment (SPA), ADCOM
meeting related to NurOwn, the timing of a PDUFA action date for
the BLA for NurOwn, the clinical development of NurOwn as a therapy
for the treatment of ALS, the future availability of NurOwn to
patients, and the future success of BrainStorm. All statements,
other than statements of historical fact, contained in this press
release are forward-looking statements. Forward-looking statements
contained in this press release may be identified by the use of
words such as "anticipate," "believe," "contemplate," "could,"
"estimate," "expect," "intend," "seek," "may," "might," "plan,"
"potential," "predict," "project," "target," "aim," "should,"
"will" "would," or the negative of these words or other similar
expressions, although not all forward-looking statements contain
these words. Forward-looking statements are based on BrainStorm's
current expectations and are subject to inherent uncertainties,
risks and assumptions that are difficult to predict. These
potential risks and uncertainties include, without limitation,
management's ability to successfully achieve its goals,
BrainStorm's ability to raise additional capital, BrainStorm's
ability to continue as a going concern, prospects for future
regulatory approval of NurOwn, whether BrainStorm's future
interactions with the FDA will have productive outcomes, and other
factors detailed in BrainStorm's annual report on Form 10-K and
quarterly reports on Form 10-Q available
at http://www.sec.gov. These factors should be considered
carefully, and readers should not place undue reliance on
BrainStorm's forward-looking statements. The forward-looking
statements contained in this press release are based on the
beliefs, expectations, and opinions of management as of the date of
this press release. We do not assume any obligation to update
forward-looking statements to reflect actual results or assumptions
if circumstances or management's beliefs, expectations or opinions
should change, unless otherwise required by law. Although we
believe that the expectations reflected in the forward-looking
statements are reasonable, we cannot guarantee future results,
levels of activity, performance, or achievements.
CONTACTS
Media:
Lisa Guiterman
Phone: +1 202-330-3431
lisa.guiterman@gmail.com
Logo -
https://mma.prnewswire.com/media/1166536/BrainStorm_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/brainstorm-cell-therapeutics-to-present-at-european-life-sciences-ceo-forum-302060600.html
SOURCE BrainStorm Cell Therapeutics Inc.